Laboratoires Pierre Fabre

Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company headquartered in the city of Castres, Midi-Pyrénées, France.[2]

History

Founded in 1962 by Pierre Fabre (1926-2013),[2] the company is present in over 130 countries.

In 1984, Pierre Fabre Dermatologie (PFD) was founded. In 1986, Pierre Fabre Japan was established as a joint venture with Shiseido. In 1989, vinorelbine received its marketing authorisation.[3] Laboratoires Avène were also created. In 1990, the Avène thermal spa re-opened.[4] The Pierre Fabre Immunology Centre in Saint-Julien-en-Genevois was inaugurated.

Olivier Bohuon was Chief Executive from September 2010 to April 2011.[5]

In December 2014, the Group announced to trade unions the elimination of 551 positions in France (including nearly 200 in the Midi-Pyrénées region) and in Barcelona, during a central works council meeting. The Research & Development and Medical Promotion divisions were affected. A strategic plan entitled Trajectoires 2018 was launched. Although promises of internal redeployment were made for employees in Midi-Pyrénées, unions expressed concerns about potential layoffs.[6]

In March 2025, Marie-Andrée Gamache was appointed head of the Pierre Fabre Medical Care division.[7] In the autumn of the same year, the Pierre Fabre Group inaugurated its new headquarters, named "Campus Chartreuse", in Castres.[8][9]

Business

The company is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products.

The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international).[2]

Laboratories Pierre Fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in France.[2]

Products

Pierre Fabre is best known for its vinorelbine (Navelbine),[10][11] an anticancer drug[12] of the vinca alkaloid class.[13][14][15]

They also developed vinflunine,[16] a fluorinated vinca alkaloid derivative[17][18] available in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen."[19]

Patents

• Pierre Fabre holds a patent for the combination of ciclopirox olamine and piroctone olamine.[20] These two active substances are highly effective when used together, creating a powerful treatment for dandruff and seborrheic dermatitis.[21]

The Pierre Fabre Foundation

The Pierre Fabre Foundation was recognized as a public utility in 1999,[22] and its mission is to enable communities from less advanced and emerging countries, as well as those plunged into severe crisis by political or economic upheaval and/or natural disaster, to access the quality and levels of everyday health care and the widely-used drugs defined by the WHO and other organisations as essential to human health.[23]

External links

• Pierre Fabre laboratories - Official site